ALLO
Allogene Therapeutics Inc
$
1.240
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.280
Open
1.250
VWAP
1.23
Vol
1.65M
Mkt Cap
275.13M
Low
1.210
Amount
2.03M
EV/EBITDA(TTM)
--
Total Shares
208.78M
EV
-1.89M
EV/OCF(TTM)
--
P/S(TTM)
--
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
--
--
-0.234
-12.02%
--
--
-0.224
-19.91%
--
--
-0.247
-11.9%
Estimates Revision
The market is revising Downward the revenue expectations for Allogene Therapeutics, Inc. (ALLO) for FY2025, with the revenue forecasts being adjusted by -59.95% over the past three months. During the same period, the stock price has changed by 12.73%.
Revenue Estimates for FY2025
Revise Downward
-59.95%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.86%
In Past 3 Month
Stock Price
Go Up
+12.73%
In Past 3 Month
10 Analyst Rating
Wall Street analysts forecast ALLO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLO is 9.40 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
2 Hold
1 Sell
Moderate Buy
Current: 1.240
Low
7.00
Averages
9.40
High
14.00
Current: 1.240
Low
7.00
Averages
9.40
High
14.00
Oppenheimer
Oppenheimer
Outperform
to
Outperform
downgrade
$9 -> $7
2025-08-01
Reason
Oppenheimer
Oppenheimer
Price Target
$9 -> $7
2025-08-01
downgrade
Outperform
to
Outperform
Reason
Oppenheimer lowered the firm's price target on Allogene Therapeutics to $7 from $9 and keeps an Outperform rating on the shares. The company closed the ALLO-647 arm of the Phase 2 ALPHA3 study and will not pursue further trials with it after a death, the analyst tells investors in a research note. The firm is more concerned about the death's impact on trial enrollment than it is about the ramifications of removing ALLO-647 might have on efficacy. However, it still thinks ALPHA3 "is a worthy endeavor that has the potential to be paradigm-changing."
JPMorgan
Brian Cheng
Overweight -> Neutral
downgrade
2025-08-01
Reason
JPMorgan
Brian Cheng
Price Target
2025-08-01
downgrade
Overweight -> Neutral
Reason
JPMorgan analyst Brian Cheng downgraded Allogene Therapeutics to Neutral from Overweight with no price target after the company reported a fatal event in cemacabtagene ansegedleucel, or cema-cel's, pivotal front-line consolidation large B-cell lymphoma ALPHA 3 study. The announcement "came as a surprise," says the analyst, who finds it "difficult to remain confident in cema-cel" following a recent series of setbacks. After updating the firm's model to reflect today's announcement, the firm is lowering penetration assumptions and probability of success for cema-cel in first-line consolidation LBCL, the analyst noted.
Citizens JMP
Outperform -> Market Perform
downgrade
2025-05-14
Reason
Citizens JMP
Price Target
2025-05-14
downgrade
Outperform -> Market Perform
Reason
Citizens JMP downgraded Allogene Therapeutics to Market Perform from Outperform without a price target post the Q1 report. The firm cites a lack of near-term milestones and longer than expected ALPHA3 development timelines for the downgrade. The firm removed the ALLO-501A revenues from its model, which was the lead program driving its valuation methodology for the shares.
Piper Sandler
Overweight
maintain
$9 -> $7
2025-05-14
Reason
Piper Sandler
Price Target
$9 -> $7
2025-05-14
maintain
Overweight
Reason
Piper Sandler lowered the firm's price target on Allogene Therapeutics to $7 from $9 and keeps an Overweight rating on the shares. The firm notes the company reported its Q1 2025 earnings where the next data update from the ALPHA3 trial of cema-cel in the first line consolidation setting has been pushed to the first half of 2026 from mid-2025. Main reasons for the delay include inadequate staffing at sites and patient retention for initial MRD testing.
Baird
Jack Allen
Outperform
downgrade
$12 -> $9
2025-05-14
Reason
Baird
Jack Allen
Price Target
$12 -> $9
2025-05-14
downgrade
Outperform
Reason
Baird analyst Jack Allen lowered the firm's price target on Allogene Therapeutics to $9 from $12 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where its ALPHA3 Lymphodepletion decision and ALLO-329 data was pushed to 1H26.
Oppenheimer
Oppenheimer
Outperform
maintain
$10 -> $9
2025-05-14
Reason
Oppenheimer
Oppenheimer
Price Target
$10 -> $9
2025-05-14
maintain
Outperform
Reason
Oppenheimer lowered the firm's price target on Allogene Therapeutics to $9 from $10 and keeps an Outperform rating on the shares following quarterly results. The most notable update was that ALPHA3's first update is being pushed back 6 months. Management said that sites were taking longer to recruit patients than anticipated-and they took full responsibility for it, the firm says.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Allogene Therapeutics Inc (ALLO.O) is -1.29, compared to its 5-year average forward P/E of -4.71. For a more detailed relative valuation and DCF analysis to assess Allogene Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.71
Current PE
-1.29
Overvalued PE
-0.27
Undervalued PE
-9.15
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.53
Current EV/EBITDA
-0.41
Overvalued EV/EBITDA
0.70
Undervalued EV/EBITDA
-7.76
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
28428.96
Current PS
1.24
Overvalued PS
106857.80
Undervalued PS
-49999.88
Financials
Annual
Quarterly
FY2025Q2
0.00
Total Revenue
FY2025Q2
YoY :
-18.07%
-54.44M
Operating Profit
FY2025Q2
YoY :
-23.23%
-50.94M
Net Income after Tax
FY2025Q2
YoY :
-34.29%
-0.23
EPS - Diluted
FY2025Q2
YoY :
-38.55%
-39.07M
Free Cash Flow
FY2025Q2
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q2
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q2
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 241.06% over the last month.
Sold
0-3
Months
46.2K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
115.8K
USD
3
0-12
Months
221.3K
USD
7
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
60.0K
Volume
Months
6-9
1
1,000K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 241.06% over the last month.
Sold
0-3
Months
46.2K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
115.8K
USD
3
0-12
Months
221.3K
USD
7
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ALLO News & Events
Events Timeline
2025-08-13 (ET)
2025-08-13
16:12:16
Allogene Therapeutics reports Q2 EPS (23c), consensus (27c)
2025-08-01 (ET)
2025-08-01
08:36:35
Allogene Therapeutics selects lymphodepletion regimen for ALPHA3 study
2025-06-01 (ET)
2025-06-01
16:40:17
Allogene Therapeutics provides updated Phase 1 TRAVERSE study of ALLO-316
Sign Up For More Events
Sign Up For More Events
News
9.0
10-10NASDAQ.COMCDTX Shares Rise Following FDA's Breakthrough Therapy Designation for CD388 in Influenza
4.0
10-10BenzingaKeysight Analyst Changes Stance; Check Out the Top 5 Downgrades for Friday
4.0
10-10BenzingaJP Morgan Lowers Allogene Therapeutics Rating to Underweight
Sign Up For More News
People Also Watch
FBIZ
First Business Financial Services Inc
50.610
USD
+3.03%
GILT
Gilat Satellite Networks Ltd
14.490
USD
+1.19%
CRMT
America's CAR-MART Inc
22.240
USD
+1.28%
CCIX
Churchill Capital Corp IX
10.710
USD
-0.37%
ILLR
Triller Group Inc
0.574
USD
+1.78%
APEI
American Public Education Inc
33.490
USD
-2.48%
WOW
WideOpenWest Inc
5.130
USD
0.00%
POET
POET Technologies Inc
6.440
USD
+0.94%
MSB
Mesabi Trust
34.140
USD
-2.21%
PRME
Prime Medicine Inc
4.940
USD
+13.56%
FAQ
What is Allogene Therapeutics Inc (ALLO) stock price today?
The current price of ALLO is 1.24 USD — it has increased 2.48 % in the last trading day.
What is Allogene Therapeutics Inc (ALLO)'s business?
What is the price predicton of ALLO Stock?
What is Allogene Therapeutics Inc (ALLO)'s revenue for the last quarter?
What is Allogene Therapeutics Inc (ALLO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Allogene Therapeutics Inc (ALLO)'s fundamentals?
How many employees does Allogene Therapeutics Inc (ALLO). have?